News
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
In interim analysis of phase 2 ASC2ESCALATE trial, patients with chronic-phase chronic myeloid leukemia who fail to respond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback